Cipla up 3 pc as USFDA gives final nod to anti-asthma product

Shares of Cipla today rose by nearly 3 per cent after the company said it has received final approval from the US health regulator for a suspension product used for treatment of asthma.
The stock gained 2.64 per cent to settle at Rs 608.65 on BSE. During the day, it rose by 3.62 per cent to Rs 614.50.
Cipla was the top gainer among the 30-share index.
On NSE, shares of the company went up by 2.64 per cent to end at Rs 608.55.
In a BSE filing today, Cipla said "it has received final approval for its abbreviated new drug application (ANDA) for Budesonide Inhalation Suspension, 0.25mg/2mL, 0.5mg/2mL, and 1mg/2mL from the United States Food and Drug Administration (USFDA)".

The approved product is a generic version of Astrazeneca's Pulmicort Respules, it added.
Pulmicort Respules are indicated for maintenance treatment of asthma and as prophylactic therapy in children of 12 months to 8 years.